methysergide (Sansert)
Jump to navigation
Jump to search
Introduction
Tradename: Sansert.
Indications
Contraindications
- peripheral vascular disease
- pulmonary disease
- severe hypertension
- phlebitis
- serious infections
- impaired renal or hepatic function
Dosage
- 4-8 mg PO QD
- do NOT give continuously for more than 6 months
- taper dose for 2-3 week period prior to discontinuation to avoid rebound headache
Tabs: 2 mg.
Adverse effects
- common (> 10%)
- insomnia, orthostatic hypotension, nausea/vomiting, abdominal pain, diarrhea, peripheral ischemia
- less common (1-10%)
- uncommon (< 1%)
- fibrosis, insomnia, overstimulation, drowsiness, mild euphoria, lethargy, depression, vertigo, unsteadiness, confusion, hyperesthesia, visual disturbances
- other
- retroperitoneal fibrosis*
- pleural & pulmonary fibrosis*
- fibrotic* thickening of cardiac valves
- rebound headache may occur if methysergide is discontinued abruptly
* Fibrosis rarely occurs if therapy is interrupted for 3-4 weeks every 6 months